Licensing and Commercialization Agreement with Novartis Pharma AG (Tables)

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of the components of the Company's collaboration revenue

Below is a summary of the components of the Company’s collaboration revenue for the three and nine months ended September 30, 2016 and September 30, 2015:

	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
License revenue	$	—	$	—	$	22,937	$	38,083
Research and development activity revenue	1,664		1,594		8,089		6,768
API transfer revenue	—		1,851		14,545		1,851
Joint operating committee revenue	4		3		16		21
Total collaboration revenue	$	1,668	$	3,448	$	45,587	$	46,723